Christopher S. Strouse

Hematology
200 Hawkins Dr
Iowa City, IA 52242

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications

From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma.

From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma.

Journal: Expert review of hematology
Published: May 27, 2026

Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC.

Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC.

Journal: Current oncology (Toronto, Ont.)
Published: March 17, 2026

The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population-Based Analysis.

The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population-Based Analysis.

Journal: American journal of hematology
Published: February 13, 2026

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3.

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3.

Journal: Cancer
Published: January 16, 2026

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Journal: Transplantation and cellular therapy
Published: January 14, 2026

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC Group.

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC Group.

Journal: Cancers
Published: December 12, 2025

Outcomes of pPCL Diagnosed Using the IMWG 2021 Consensus Definition: A Retrospective Multicenter Analysis.

Outcomes of pPCL Diagnosed Using the IMWG 2021 Consensus Definition: A Retrospective Multicenter Analysis.

Journal: Cancers
Published: October 12, 2025

Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation.

Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation.

Journal: JCO oncology practice
Published: October 02, 2025

Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals.

Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals.

Journal: Cancers
Published: September 19, 2025

BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal Impairment.

BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal Impairment.

Journal: Current oncology (Toronto, Ont.)
Published: September 15, 2025

Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study.

Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study.

Journal: Blood cancer journal
Published: July 24, 2025

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.

Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.

Journal: Clinical lymphoma, myeloma & leukemia
Published: July 06, 2025
Showing 1-12 of 52

Last Updated: 09/26/2026